Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pfs25M-EPA + Alhydrogel
- Development stage
- Phase 1
- Lead developer
- Walter Reed Army Institute of Research
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Peptide-Protein Conjugates → Peptide Conjugates → Peptides
- Administration
- Intramuscular Injection
01
Overview
Pfs25M-EPA + Alhydrogel is a transmission-blocking malaria vaccine candidate composed of a recombinant protein-protein conjugate. The vaccine consists of the Pfs25M antigen—a *Pichia pastoris*-expressed recombinant form of the Plasmodium falciparum surface protein Pfs25—chemically conjugated to ExoProtein A (EPA), a carrier protein derived from *Escherichia coli*. This conjugate is formulated with Alhydrogel, an aluminum hydroxide adjuvant, to enhance immunogenicity. The primary mechanism involves inducing antibodies against the mosquito-stage ookinete surface antigen (Pfs25), thereby blocking parasite development in mosquitoes and interrupting malaria transmission. Developed for intramuscular administration, this subunit vaccine has been evaluated in preclinical and clinical studies for safety and immunogenicity[1][2][4].
02
Targets
Pfs25
Beyond the preview
Go deeper on Pfs25M-EPA + Alhydrogel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pfs25M-EPA + Alhydrogel.